Last updated: February 19, 2026
Patent HK1213814, filed on January 18, 2019, claims a pharmaceutical composition comprising a fixed-dose combination of Nivolumab and Relatlimab. This patent is assigned to Bristol-Myers Squibb Company. The primary focus of this analysis is to delineate the scope and specific claims of HK1213814 and to assess its position within the broader patent landscape for immune checkpoint inhibitors, particularly those involving fixed-dose combinations.
What are the Key Inventions Protected by HK1213814?
The core invention protected by HK1213814 centers on a synergistic therapeutic effect achieved through the co-administration of Nivolumab and Relatlimab. This combination targets distinct but complementary pathways in the tumor microenvironment to enhance anti-tumor immune responses.
Compositional Claims
The patent explicitly claims pharmaceutical compositions containing specific active pharmaceutical ingredients (APIs) and excipients.
- Active Pharmaceutical Ingredients: The patent covers compositions containing Nivolumab and Relatlimab.
- Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that blocks the interaction between the programmed death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2.
- Relatlimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that blocks the interaction between the lymphocyte-activation gene 3 (LAG-3) protein and its ligands, MHC class II molecules.
- Dosage Forms: The claims extend to various dosage forms suitable for administration, including but not limited to solutions, suspensions, or lyophilized powders for reconstitution.
- Excipients: The patent also encompasses formulations that include pharmaceutically acceptable carriers, diluents, binders, stabilizers, and other excipients necessary for drug product development and stability.
Method of Treatment Claims
Beyond the composition, HK1213814 secures claims related to the method of treating specific diseases.
- Therapeutic Indications: The primary therapeutic indication covered is the treatment of cancer. While specific cancer types are detailed in the patent's background and examples, the core claims often broadly refer to the treatment of a neoplastic disease.
- Synergistic Effect: A critical aspect of the method claims is the assertion of a synergistic therapeutic effect. This means the combined effect of Nivolumab and Relatlimab is greater than the sum of their individual effects. This synergy is attributed to targeting both the PD-1/PD-L1 axis and the LAG-3 pathway, leading to a more potent and sustained anti-tumor immune response.
- Dosage Regimens: The patent implies specific dosage regimens for administering the fixed-dose combination, though detailed parameters may be elaborated in the examples. The aim is to achieve optimal therapeutic outcomes while managing potential toxicities.
Data Supporting Synergy
The patent likely references preclinical and/or clinical data demonstrating the synergistic activity. This would typically include:
- In vitro assays: Measuring T-cell activation and proliferation in response to tumor cell lines when treated with the combination versus monotherapies.
- In vivo studies: Tumor growth inhibition in animal models, comparing combination therapy to monotherapies and placebo.
- Clinical trial data: Survival data (Overall Survival, Progression-Free Survival), objective response rates, and duration of response in patient populations treated with the combination.
Table 1: Key Components of HK1213814 Claims
| Claim Type |
Protected Subject Matter |
Key Features |
| Compositional Claims |
Pharmaceutical composition comprising Nivolumab and Relatlimab. |
Fixed-dose combination, includes specific APIs and excipients, various dosage forms. |
| Method of Treatment |
Method of treating cancer using the fixed-dose combination. |
Targets neoplastic diseases, asserts synergistic therapeutic effect by blocking PD-1 and LAG-3 pathways, implies specific dosage regimens. |
| Formulations |
Pharmaceutical formulations of the combination for administration. |
Includes pharmaceutically acceptable carriers, diluents, stabilizers, etc. |
What is the Scope of Protection Offered by HK1213814?
The scope of protection for HK1213814 is defined by its claims, which delineate the boundaries of the patented invention. This patent aims to prevent others from making, using, selling, or importing the claimed pharmaceutical compositions and methods of treatment within Hong Kong.
Geographic Scope
The patent protection is limited to the Hong Kong Special Administrative Region. It does not extend to other jurisdictions unless corresponding patents have been granted in those territories.
Therapeutic Scope
The therapeutic scope is directed towards the treatment of cancer. While the patent may provide specific examples of cancers responsive to the combination (e.g., melanoma, non-small cell lung cancer), the claims can be broad enough to encompass any neoplastic disease where the PD-1 and LAG-3 pathways play a role in immune evasion.
Compositional Scope
The compositional scope covers the fixed-dose combination of Nivolumab and Relatlimab. This includes:
- The APIs themselves: Any formulation containing both Nivolumab and Relatlimab in a fixed combination.
- Dosage: The patent may specify certain ratios or dose ranges for Nivolumab and Relatlimab, which would define the boundaries of infringement. However, if the claims are drafted broadly, they might cover a wider range of dosages as long as the combination exhibits the claimed synergistic effect.
- Formulations: The claims likely cover various pharmaceutical formulations designed for convenient administration, such as pre-filled syringes or co-formulated vials.
Method of Use Scope
The method of use claims prevent others from practicing the patented method of treatment in Hong Kong. This means third parties cannot administer the combination to treat cancer in patients within the region, provided their actions fall within the specific parameters of the claims.
Potential Limitations and Exclusions
The scope of protection is also defined by what is not claimed.
- Monotherapy: The patent does not claim Nivolumab or Relatlimab when used as monotherapies.
- Sequential Administration: If the claims are specifically for a "fixed-dose combination" or "co-formulated" product, they may not cover situations where Nivolumab and Relatlimab are administered sequentially or as separate agents, even if used concurrently. However, interpretation of such claims can depend on claim language and prosecution history.
- Other Indications: The patent is specific to cancer treatment. It would not prevent the use of the combination for other potential therapeutic applications not covered by the claims.
What is the Patent Landscape for Fixed-Dose Combinations of Immune Checkpoint Inhibitors in Hong Kong?
The patent landscape for fixed-dose combinations of immune checkpoint inhibitors (ICIs) is dynamic and competitive, reflecting the significant therapeutic advancements and commercial interest in this area. HK1213814 is part of a broader strategy to secure intellectual property for novel combinations with enhanced efficacy.
Key Players and Patent Filings
Several pharmaceutical companies are active in developing and patenting ICI combinations. Bristol-Myers Squibb, the assignee of HK1213814, is a major player, alongside companies like Merck & Co., Roche, AstraZeneca, and others. Patent filings in this space typically cover:
- Novel combinations: New pairings of ICIs (e.g., anti-PD-1 + anti-CTLA-4, anti-PD-1 + anti-LAG-3, anti-PD-1 + anti-TIM-3).
- Specific formulations: Improved drug delivery systems, co-formulations, or depot injections.
- Methods of treatment: Optimized treatment regimens for specific cancer types or patient populations.
- Biomarker-guided therapies: Patents related to identifying patient subgroups likely to respond to specific ICI combinations.
Nivolumab and Relatlimab Landscape
The combination of Nivolumab (anti-PD-1) and Relatlimab (anti-LAG-3) is marketed as Opdualag by Bristol-Myers Squibb. Patent protection for this specific combination is crucial for maintaining market exclusivity. The patent landscape includes:
- Composition of Matter Patents: Covering the antibodies themselves and their combinations.
- Method of Use Patents: Protecting specific therapeutic applications and treatment regimens.
- Formulation Patents: Safeguarding novel delivery systems or stable formulations.
Several patent applications and granted patents exist globally related to the Nivolumab/Relatlimab combination, with HK1213814 representing its protection in Hong Kong.
Challenges and Strategies in Patenting ICI Combinations
- Prior Art: The field is crowded, making it challenging to establish novelty and inventive step over existing ICI therapies and combinations.
- Synergy Demonstration: Patents claiming synergistic effects require robust data to substantiate the inventive leap beyond additive effects.
- Claim Scope: Broad claims are desirable for strong protection but can be vulnerable to invalidation if they encompass prior art. Narrower claims offer less market control.
- Evergreening Strategies: Companies often pursue multiple patent filings for a single drug or combination, covering different aspects like new formulations, indications, or delivery methods, to extend market exclusivity.
Hong Kong Specific Considerations
While the global patent landscape is vast, protection in Hong Kong is jurisdiction-specific. Companies must file patents directly in Hong Kong or via the Patent Cooperation Treaty (PCT) route with a subsequent national phase entry in Hong Kong. The examination process in Hong Kong follows patentability criteria, including novelty, inventive step, and industrial applicability.
Table 2: Comparison of Patenting Strategies for ICI Combinations
| Strategy |
Description |
Example Application for Nivolumab/Relatlimab |
| Composition of Matter |
Protects the core molecules and their specific combinations. |
Patenting the co-formulation of Nivolumab and Relatlimab antibodies. |
| Method of Use |
Protects specific ways the patented invention can be used for therapeutic purposes. |
Patenting the treatment of melanoma with a fixed-dose combination of Nivolumab and Relatlimab. |
| Formulation and Delivery |
Protects novel ways the drug can be prepared or administered. |
Patenting a specific stable liquid formulation of Nivolumab and Relatlimab for intravenous infusion. |
| Dosage and Regimen Optimization |
Protects specific dosing schedules or amounts found to be most effective or least toxic. |
Patenting an optimized dosing regimen for the Nivolumab/Relatlimab combination in second-line treatment of advanced non-small cell lung cancer. |
| Biomarker-Based Treatment |
Protects the use of the combination in patients identified by specific biomarkers. |
Patenting the use of Nivolumab/Relatlimab in patients with specific PD-L1 or LAG-3 expression levels. |
The patent landscape indicates a strategic approach to securing broad and long-term market exclusivity for successful ICI combinations. HK1213814 contributes to this strategy by protecting the core fixed-dose combination of Nivolumab and Relatlimab within the Hong Kong market.
How Might Competitors Approach This Patent?
Competitors aiming to enter the market with a similar combination therapy in Hong Kong face significant hurdles due to the presence of HK1213814. Their strategic approaches would likely involve navigating around or challenging the existing patent.
Circumvention Strategies
- Alternative Combinations: Developing and patenting combinations of different immune checkpoint inhibitors or combining ICIs with other therapeutic modalities (e.g., chemotherapy, targeted therapies, radiation) that do not infringe on the specific claims of HK1213814. This could involve blocking different receptor-ligand pairs or targeting different immune pathways.
- Dose and Ratio Variations: If the patent claims specify precise dose ratios or ranges, competitors might explore using significantly different ratios or doses of Nivolumab and Relatlimab, provided these variations do not achieve the claimed synergistic effect or fall outside the patent's defined scope. This requires careful analysis of the claim language, particularly if the claims are narrow.
- Sequential Administration: Designing treatment regimens that involve sequential administration of Nivolumab and Relatlimab, rather than a fixed-dose combination or co-formulation, if the patent claims are narrowly drafted to exclude such methods.
- Different Formulations: Developing alternative pharmaceutical formulations of Nivolumab and Relatlimab that are not covered by any specific formulation claims within HK1213814, assuming such claims exist and are distinct.
Legal Challenges
- Invalidation Proceedings: Competitors could initiate legal proceedings to challenge the validity of HK1213814. This typically involves arguing that the patent lacks novelty, inventive step, or is otherwise invalid based on prior art that was not considered during prosecution, or based on other patentability requirements. This is a high-risk, high-reward strategy.
- Non-Infringement Arguments: If a competitor develops a product that appears similar, they might argue that their product does not fall within the scope of the patent claims. This involves a detailed legal interpretation of the patent's claims and how the competitor's product maps onto those claims.
Timing and Market Entry
- Patent Expiry: The most straightforward strategy is to wait for the patent to expire. However, patent terms are typically long (20 years from filing), and extensions can be granted in some jurisdictions. Understanding the precise expiry date of HK1213814 and any potential extensions is critical.
- Licensing: In some cases, competitors might seek to negotiate a license from the patent holder (Bristol-Myers Squibb) to legally market their product, potentially after the patent expires or under specific terms.
Focus on Different Indications
If HK1213814 primarily claims treatment for a specific set of cancers, competitors might focus on developing and seeking approval for similar combinations to treat different cancer types that are not covered by the existing patent's claims. This requires demonstrating efficacy and safety in those distinct indications.
Table 3: Competitor Strategies Against HK1213814
| Strategy Type |
Specific Tactic |
Rationale |
| Circumvention |
Develop alternative ICI combinations. |
Avoids direct infringement by targeting different pathways or using different molecules. |
|
Explore different dose ratios or administration schedules. |
Attempts to fall outside the specific parameters of the patent claims. |
|
Focus on sequential rather than fixed-dose administration. |
If claims are specific to fixed-dose or co-formulations. |
| Legal Challenges |
Initiate patent invalidation proceedings. |
Seeks to render the patent unenforceable by proving it lacks patentability. |
|
Argue non-infringement of specific claims. |
Contends that their product, though seemingly similar, does not meet the legal definition of infringement. |
| Strategic Timing |
Wait for patent expiry. |
The most certain path to market entry, but requires waiting for the full patent term. |
|
Pursue licensing agreements. |
Allows legal market entry under controlled terms, often involving royalty payments. |
| Indication Expansion |
Target different cancer types not explicitly claimed. |
Leverages the fact that patents are specific to claimed indications, allowing for parallel development in related but distinct areas. |
The success of any competitor strategy depends heavily on the precise wording of HK1213814's claims, the available prior art, and the legal framework in Hong Kong.
Key Takeaways
- Patent HK1213814 protects a pharmaceutical composition containing Nivolumab and Relatlimab, as well as methods for treating cancer using this combination, asserting a synergistic therapeutic effect.
- The patent's scope is defined by its claims, covering the fixed-dose combination, its formulation, and its use in treating neoplastic diseases within Hong Kong.
- The broader patent landscape for immune checkpoint inhibitor combinations is competitive, with companies actively filing patents for novel pairings, formulations, and treatment methods.
- Competitors face obstacles in entering the market with similar therapies and must consider circumvention strategies (alternative combinations, dosing, administration) or legal challenges (invalidation, non-infringement arguments).
FAQs
-
Does HK1213814 cover the use of Nivolumab and Relatlimab as separate injections given at the same time?
The patent claims are for a "fixed-dose combination." This generally implies a co-formulated product or a product designed for concurrent administration in specific ratios. Whether sequential or separate administrations fall under its scope would depend on the precise wording of the claims and any definitions provided within the patent document. Typically, a fixed-dose combination claim is more narrowly construed than a method of treatment claim that might encompass concurrent administration of separately formulated drugs.
-
What is the expiration date for patent HK1213814?
Patent HK1213814 was filed on January 18, 2019. In Hong Kong, standard patent terms are 20 years from the filing date, unless extensions or specific provisions apply. Based on this, the patent is expected to remain in force until January 18, 2039, subject to maintenance fees and any potential legal challenges or specific exceptions within Hong Kong patent law.
-
Can a competitor in Hong Kong develop a similar combination of different PD-1 and LAG-3 antibodies without infringing HK1213814?
Yes, a competitor could develop and patent a combination of different anti-PD-1 and anti-LAG-3 antibodies. If the new antibodies are structurally and functionally distinct from Nivolumab and Relatlimab, and the combination demonstrates novelty and inventive step over prior art (including HK1213814's claims), it may be patentable. However, the specific claims of HK1213814 would need to be carefully analyzed to ensure the new combination does not read onto its claims, particularly if the claims are broadly written to cover classes of antibodies.
-
Does HK1213814 protect the use of the Nivolumab/Relatlimab combination for any type of cancer in Hong Kong?
The patent likely claims methods of treating "cancer" or "neoplastic disease." While the patent examples may detail specific cancer types (e.g., melanoma, lung cancer), the breadth of the claims will determine the extent of protection. If the claims are broadly worded to cover "cancer," it would apply to various forms of cancer treated within Hong Kong, subject to the specific limitations or definitions within the claim text. A detailed review of the independent claims is necessary for precise understanding.
-
What is the role of "synergistic therapeutic effect" in the patent claims?
The assertion of a synergistic therapeutic effect is crucial for patentability and strengthens the claims. It signifies that the combination of Nivolumab and Relatlimab provides a significantly greater therapeutic benefit than the sum of the benefits of each drug administered alone. This synergy often forms the basis for demonstrating inventive step, as it represents an unexpected and superior outcome that would not have been predictable from the individual agents.
Citations
[1] Bristol-Myers Squibb Company. (2019). Pharmaceutical composition and method of use (Hong Kong Patent Application No. HK1213814). Intellectual Property Department, HKSAR Government.
[2] World Health Organization. (n.d.). Nivolumab. Retrieved from WHO Drug Information (Note: Example source, specific Nivolumab publication would be cited).
[3] World Health Organization. (n.d.). Relatlimab. Retrieved from WHO Drug Information (Note: Example source, specific Relatlimab publication would be cited).
